Clinical Trial Update: A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease [Phase 3]

View source ↗

Summary

A Phase 3 study comparing guselkumab to risankizumab in participants with moderately to severely active Crohn's disease; the trial status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Guselkumab (guselkumab)
• Risankizumab (risankizumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Crohn Disease | Phase 3 | Status: NOT_YET_RECRUITING